TABLE 1.
Mouse models of pneumonia
| Route of infection | Mouse strain(s) | Pneumococcal serotype(s) | Aim(s) of study | Readouts | Utility | Reference(s) |
|---|---|---|---|---|---|---|
| i.t. | C57BL/6 | 3 | Antibiotic efficacy, model description | CFU, histology, survival, pharmacokinetics | Drug efficacy and pharmacokinetics | 12 |
| i.t. | ddY | NSa | Gastric juice in pneumonia | Survival, CFU, PMNb, lung histology | Pathogenesis of pneumonia in the elderly | 114 |
| i.n. | MF1 | 2 | Role of pneumolysin and autolysin, model description | CFU, lung histology | Host-parasite interaction, disease pathogenesis, vaccine and drug studies | 50 |
| i.n. | Neonatal and infant NMRI | 1 | Immunization in early life | Antibody titers, CFU | Neonatal and early-life vaccinology | 115 |
| i.n. | BALB/c and OF1 | 14 (for BALB/c) and 3, 9 (for OF1) | Therapy in neutropenic mice | CFU, survival, pharmacokinetics | Antibiotic efficacy, immunotherapy studies | 201, 223 |
| i.n. | CBA/J | 3, 11, 19 | Model of penicillin-resistant pneumonia | Survival, CFU, histology, pharmacokinetics | Antibiotic efficacy in immunocompetent mice | 234 |
| Aerosol nebulizer | CBA/J | 28 | Model of chronic obstructive pneumonia | CFU, serum immunoglobulin G | Disease pathogenesis | 113 |
| Aerosol nebulizer | CBA/J | 3 | Low-dose model, drug efficacy | Survival, CFU, histology | Efficacy of tissue-directed antimicrobials | 176 |
a
NS, not specified.
b
PMN, polymorphonuclear cells.